Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 10/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | BRD1 | O95696 | 3/20 | 0.38 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112574 | 1.00 | BRPF1 (0.47) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL21148933 | 0.84 | BRPF1 (0.41) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL20908218 | 0.84 | BRPF1 (0.41) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL21112831 | 0.75 | EGLN1 (0.33) | MEN1CYP1A2KMT2A | |
| SCHEMBL21112828 | 0.75 | EGLN1 (0.33) | MEN1CYP1A2KMT2A | |
| SCHEMBL762351 | 0.75 | BRPF1 (0.59) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL20900144 | 0.73 | CA12 (0.43) | CA12CA9MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL21112668 | 0.72 | CA12 (0.42) | CA12CA9MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL21112670 | 0.72 | CA12 (0.42) | CA12CA9MEN1CYP1A2KMT2A | |
| Flucarbril SCHEMBL2109672 | 0.70 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | BRPF1 3176/4885BRD4 1637/4885BRD9 3034/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | BRPF1 3176/4885BRD4 1637/4885BRD9 3034/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | BRPF1 3176/4885BRD4 1637/4885BRD9 3034/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | BRPF1 2515/4885BRD4 2157/4885BRD9 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.